Cubist Pharmaceuticals, Inc. (CBST) Announces Submission Of New Drug Application For Investigational Antibiotic Ceftolozane/Tazobactam
4/21/2014 9:19:20 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of its investigational antibiotic ceftolozane/tazobactam for the treatment of Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI).
Help employers find you! Check out all the jobs and post your resume.
comments powered by